Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

Sponsor
National and Kapodistrian University of Athens
Study ID
NCT07653412
Status
Recruiting
Apply to this trial

Conditions

  • Anti-obesity Agents
  • Obesity (Disorder)
  • Precision Medicine

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide or Tirzepatide — DRUG
    Adults with obesity initiating treatment with semaglutide or tirzepatide as part of routine clinical care. Participants are followed prospectively for 6 months to evaluate weight loss response and its association with genetic risk score.

Study Details

Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes. The aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.

Key Dates

Start date
Apr 22, 2026
Status verified
Jun 2026
Primary completion
Jan 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
220 participants (estimated)

Arms

  • Arm: Semaglutide or Tirzepatide
    Adults with obesity initiating treatment with semaglutide or tirzepatide as part of routine clinical care. Participants are followed prospectively for 6 months to evaluate weight loss response and its association with genetic risk score.

Primary Outcome Measure

Percentage weight loss at 6 months [ Time Frame: 6 months ]

Central Contacts

Related Studies